

Children's Mercy Kansas City

**SHARE @ Children's Mercy**

---

Research Month 2021

Research at Children's Mercy Month

---

5-2021

## **Low Dose Doxorubicin Inhibits Immune Checkpoint Upregulation In Acute Leukemias**

Bradley C. Stockard

Jacqelyn Nemechek

Kealan Schroeder

Jennifer Pace

John M. Perry

Follow this and additional works at: [https://scholarlyexchange.childrensmercy.org/research\\_month2021](https://scholarlyexchange.childrensmercy.org/research_month2021)

---

# Low Dose Doxorubicin Inhibits Immune Checkpoint Upregulation In Acute Leukemias

Bradley Stockard, Jacquelyn Nemechek, Kealan Schroeder, Jennifer Pace, John Perry

## INTRODUCTION

- Chemoresistant leukemia stem cells (LSCs) can cause relapse in leukemia
- Doxorubicin (DXR) has been identified as an inhibitor of an immune checkpoint (IC) mechanism of resistance
- Objective: determine the DXR doses that inhibit IC expression upregulation in vitro

## METHODS

- Kasumi and Jurkat cell lines were treated with low and high doses of DXR determined by previous kill curve experiments
- Cells were collected at 12h timepoints over the course of 48h and analyzed for expression of CTLA-4, PD-1, PD-L1, TIGIT, and TIM-3 via flow cytometry
- Statistical analysis was done using Tukey's multiple comparisons test

## Multiple immune checkpoints show significantly lower expression in low dose doxorubicin treated leukemia cells compared to cells treated with chemotherapeutic dose doxorubicin.




Figure 1: Bar graphs showing expression of CTLA-4, TIGIT, and TIM-3 immune checkpoints in Kasumi and Jurkat cells. Expression is measured as the percent frequency of the parent cell population detected.

## RESULTS

- 25 nM DXR treated Kasumi cells showed significantly lower CTLA-4, TIGIT, and TIM-3 expression at 36h ( $p < 0.0001$ ) and 48h ( $p < 0.001$ )
- 10 nM DXR treated Jurkat cells showed significantly lower CTLA-4, TIGIT, and TIM-3 expression at 36h ( $p < 0.01$ ) and 48h ( $p < 0.0001$ )
- TIGIT and TIM-3 also showed lower expression at 24h ( $p < 0.0001$ )

## DISCUSSION

- Results show that in mixed cell populations, low dose DXR prevents the upregulation of multiple ICs within the first two days of treatment
- Overall, this presents a promising strategy for preventing a mechanism of resistance using an established chemotherapeutic agent

LOVE WILL.



Take a picture to download the presenter's contact information